CTTC ....BREAKOUT NEWS JUST OUT !!! : >
Calmare Therapeutics Awarded GSA Contract Extension
Simple Buying Process of Calmare® Pain Therapy Devices and its Consumables for U.S. Military Hospitals, Clinics and Medical Practitioners Extended
Business Wire Calmare Therapeutics Incorporated
52 minutes ago
FAIRFIELD, Conn.--(BUSINESS WIRE)--
Calmare Therapeutics Incorporated, (CTTC) (CTI), the pain mitigation company, has been awarded a preliminary three-month extension of its General Services Administration (GSA) military contract (V797P-4300B). First awarded in 2010, CTI’s contract extension is designed to continue the streamlined procurement process for U.S. military personnel and their families and institutional customers across the globe who acquire Calmare® Pain Therapy Devices and its consumables.
“This extension allows us to continue offering our Calmare® Pain Therapy device to U.S. military personnel and their families through the U.S. Veterans Administration to reduce and/or eliminate chronic neuropathic pain,” said Calmare Therapeutics President & CEO Conrad Mir. “With this extension, we can broaden our military contract footprint and gain contracts with embedded device sales components that will drive revenues – the Company’s prime directive in pursuing U.S. government sales.”
Today, a large host of U.S. military hospitals and clinics rely on CTI’s Calmare Pain Mitigation Therapy™. Our pain mitigation solution offers comprehensive pain mitigation whereby pain may be eliminated for well over 3 to 4 months after the first full treatment regimen in those patients that are responders. With one or two booster treatments after the first course, a patient may have full pain elimination for a year of more without the toxic side effects or addictive qualities of prescriptions drugs and opiates.
About the Company
Calmare Therapeutics Inc., the pain mitigation company, develops and commercializes innovative wound and pain management products and technologies. CTI holds the 510k clearance on its flagship product, the non-invasive Calmare® Pain Therapy Device, which grants it an exclusive right to sell, market, research and develop the medical device. The Company is the exclusive licensed global distributor of Calmare.
Calmare Therapeutics Awarded GSA Contract Extension
Simple Buying Process of Calmare® Pain Therapy Devices and its Consumables for U.S. Military Hospitals, Clinics and Medical Practitioners Extended
Business Wire Calmare Therapeutics Incorporated
52 minutes ago
FAIRFIELD, Conn.--(BUSINESS WIRE)--
Calmare Therapeutics Incorporated, (CTTC) (CTI), the pain mitigation company, has been awarded a preliminary three-month extension of its General Services Administration (GSA) military contract (V797P-4300B). First awarded in 2010, CTI’s contract extension is designed to continue the streamlined procurement process for U.S. military personnel and their families and institutional customers across the globe who acquire Calmare® Pain Therapy Devices and its consumables.
“This extension allows us to continue offering our Calmare® Pain Therapy device to U.S. military personnel and their families through the U.S. Veterans Administration to reduce and/or eliminate chronic neuropathic pain,” said Calmare Therapeutics President & CEO Conrad Mir. “With this extension, we can broaden our military contract footprint and gain contracts with embedded device sales components that will drive revenues – the Company’s prime directive in pursuing U.S. government sales.”
Today, a large host of U.S. military hospitals and clinics rely on CTI’s Calmare Pain Mitigation Therapy™. Our pain mitigation solution offers comprehensive pain mitigation whereby pain may be eliminated for well over 3 to 4 months after the first full treatment regimen in those patients that are responders. With one or two booster treatments after the first course, a patient may have full pain elimination for a year of more without the toxic side effects or addictive qualities of prescriptions drugs and opiates.
About the Company
Calmare Therapeutics Inc., the pain mitigation company, develops and commercializes innovative wound and pain management products and technologies. CTI holds the 510k clearance on its flagship product, the non-invasive Calmare® Pain Therapy Device, which grants it an exclusive right to sell, market, research and develop the medical device. The Company is the exclusive licensed global distributor of Calmare.
